Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration

Details for Australian Patent Application No. 2008201418 (hide)

Owner Celgene Corporation

Inventors Zeldis, Jerome B.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2008201418

Parent 2003285107

Filing date 27 March 2008

Wipo publication date 24 April 2008

Acceptance publication date 18 February 2010

International Classifications

A61K 31/454 (2006.01)

A61K 31/522 (2006.01)

A61K 31/545 (2006.01) - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine

A61K 31/557 (2006.01) - Eicosanoids, e.g. leukotrienes

A61K 31/56 (2006.01) - Compounds containing cyclopenta[a]hydrophenanthrene ring systems

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61K 38/21 (2006.01) Medicinal preparations containing peptides - Interferons

A61K 38/27 (2006.01) Medicinal preparations containing peptides - Growth hormone (GH) (Somatotropin)

Event Publications

17 April 2008 Complete Application Filed

24 April 2008 Application Open to Public Inspection

  Published as AU-B-2008201418

18 February 2010 Application Accepted

  Published as AU-B-2008201418

17 June 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008201419-Molecules with extended half-lives, compositions and uses thereof

2008201417-Assembly system for floor and/or wall tiles